PubMed · 1983 · 15 citations · 19 references
GlycobiologyBlood CellThin-layer ChromatographyCellular PhysiologyIntracellular DistributionBioanalysisHematologyClinical ChemistryChromatographyCell PhysiologyBiochemistryPharmacologyCell BiologyNatural SciencesIncorporated DrugCellular BiochemistryMedicineL1210 CellsDrug Analysis
In order to clarify differences in mode of action between N4-behenoyl-1-beta-D-arabinofuranosylcytosine (behenoyl-ara-C) and 1-beta-D-arabinofuranosylcytosine (ara-C), comparative studies on both agents were undertaken. When human erythrocytes incubated with behenoyl-ara-C[acyl-1-14C] were fractionated into stroma and stroma-free lysate, a marked accumulation of radioactivity in stroma was observed. In contrast, ara-C[cytosine-2-14C] was rapidly incorporated into the stroma-free lysate. Thin-layer chromatography of the extracts of L1210 cells incubated with behenoyl-ara-C[acyl-1-14C] or behenoyl-ara-C[cytosine-2-14C] at 37 degrees for 60 min revealed that most of the incorporated drug remained as unmetabolized behenoyl-ara-C. After incubation of 20 microM behenoyl-ara-C or ara-C with L1210 cells at 37 degrees for 60 min, subcellular fractionation of the cell suspension was performed; behenoyl-ara-C was accumulated markedly in the membrane, mitochondria and microsome fractions. In contrast, most of the ara-C was found in the 105,000g supernatant fraction. The accumulation of behenoyl-ara-C in membrane structures may result from the lipophilic nature of the agent, which may have a prolonged inhibitory action on leukemic cell proliferation.
19
Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults
Rose Ruth Ellison, James F. Holland, Marise Weil et al. · Blood · 1968 · 548 citations · Full text